Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines

Rheumatology (Oxford). 2020 Apr 1;59(4):e24-e32. doi: 10.1093/rheumatology/kez640.
No abstract available

Keywords: Pneumocystis jirovecii; ANCA-associated vasculitis; hypogammaglobulinaemia; practise guideline; rituximab.

Publication types

  • Consensus Development Conference
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agammaglobulinemia / chemically induced
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / physiopathology
  • Antirheumatic Agents / therapeutic use*
  • Churg-Strauss Syndrome / drug therapy
  • Churg-Strauss Syndrome / physiopathology
  • Delphi Technique
  • Duration of Therapy
  • Granulomatosis with Polyangiitis / drug therapy
  • Granulomatosis with Polyangiitis / physiopathology
  • Humans
  • Immunocompromised Host
  • Influenza Vaccines / therapeutic use
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control
  • Maintenance Chemotherapy
  • Microscopic Polyangiitis / drug therapy
  • Microscopic Polyangiitis / physiopathology
  • Neutropenia / chemically induced
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / therapeutic use
  • Pneumonia, Pneumocystis / immunology
  • Pneumonia, Pneumocystis / prevention & control
  • Practice Guidelines as Topic
  • Recurrence
  • Rituximab / therapeutic use*
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • United Kingdom

Substances

  • Antirheumatic Agents
  • Influenza Vaccines
  • Pneumococcal Vaccines
  • Rituximab
  • Trimethoprim, Sulfamethoxazole Drug Combination